UB Paderborn / Katalog / Suche / in CDI

1 – 10 von 10

Sortiert nach

Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY3-36, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats

Nutrients, 2024-03, Vol.16 (6), p.904

2024

Link zum Volltext

Verfügbarkeit prüfen

Association of preclinical blood glucose with hospitalization rate and in‐hospital mortality: A single‐center retrospective cohort study

Journal of the American College of Emergency Physicians Open, 2024-02, Vol.5 (1), p.e13091-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Calpastatin ablation aggravates the molecular phenotype in cell and animal models of Huntington disease

Neuropharmacology, 2018-05, Vol.133, p.94-106

2018

Link zum Volltext

Verfügbarkeit prüfen

GLP-1 and PYY for the treatment of obesity: a pilot study on the use of agonists and antagonists in diet-induced rats

Endocrine Connections, 2024-03, Vol.13 (3), p.1-12

2024

Link zum Volltext

Verfügbarkeit prüfen

Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?

Pharmacology & therapeutics (Oxford), 2023-11, Vol.251, p.108549-108549, Article 108549

2023

Link zum Volltext

Verfügbarkeit prüfen

THU-269-YI Effects of semaglutide, Peptide YY3-36 and empagliflozin on metabolic dysfunctions-associated fatty steatotic liver disease in diet-induced obese rats with chronic nitric oxide synthaseinhibition

Journal of hepatology, 2024-06, Vol.80, p.S587-S588

2024

Link zum Volltext

Verfügbarkeit prüfen

Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY[sub.3-36], and Empagliflozin on Early MASLD in Diet-Induced Obese Rats

Nutrients, 2024-03, Vol.16 (6)

2024

Link zum Volltext

Verfügbarkeit prüfen

Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY 3-36 , and Empagliflozin on Early MASLD in Diet-Induced Obese Rats

Nutrients, 2024-03, Vol.16 (6)

2024

Link zum Volltext

Verfügbarkeit prüfen

Well-posedness & stability analysis for spatially interconnected systems with finite extent

2017 American Control Conference (ACC), 2017, p.1803-1808

2017

Link zum Volltext
IEEE_Xplore

1 – 10 von 10

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(9)
Mit Volltextzugriff
(10)

Publikationsform

Artikel
(9)
Tagungsberichte
(1)

Sprache

Englisch
(10)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY3-36, and Empagliflozin on Early MASLD in Diet-Induced Obese Rats

Association of preclinical blood glucose with hospitalization rate and in‐hospital mortality: A single‐center retrospective cohort study

Calpastatin ablation aggravates the molecular phenotype in cell and animal models of Huntington disease

GLP-1 and PYY for the treatment of obesity: a pilot study on the use of agonists and antagonists in diet-induced rats

Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?

THU-269-YI Effects of semaglutide, Peptide YY3-36 and empagliflozin on metabolic dysfunctions-associated fatty steatotic liver disease in diet-induced obese rats with chronic nitric oxide synthaseinhibition

Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY[sub.3-36], and Empagliflozin on Early MASLD in Diet-Induced Obese Rats

Assessing Lateralization Index of Adrenal Venous Sampling for Surgical Indication in Primary Aldosteronism

Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY 3-36 , and Empagliflozin on Early MASLD in Diet-Induced Obese Rats

Well-posedness & stability analysis for spatially interconnected systems with finite extent

Suchergebnisse filtern